Cytokinetics Inc - Asset Resilience Ratio
Cytokinetics Inc (CYTK) has an Asset Resilience Ratio of 47.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CYTK working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Cytokinetics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CYTK asset base.
Liquid Assets Composition Over Time
This chart breaks down Cytokinetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Cytokinetics Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $910.41 Million | 47.31% |
| Total Liquid Assets | $910.41 Million | 47.31% |
Asset Resilience Insights
- Very High Liquidity: Cytokinetics Inc maintains exceptional liquid asset reserves at 47.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytokinetics Inc Industry Peers by Asset Resilience Ratio
Compare Cytokinetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
Annual Asset Resilience Ratio for Cytokinetics Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Cytokinetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.33% | $759.70 Million | $1.42 Billion | -16.67pp |
| 2024-12-31 | 70.00% | $981.16 Million | $1.40 Billion | +9.12pp |
| 2023-12-31 | 60.87% | $501.80 Million | $824.32 Million | -9.78pp |
| 2022-12-31 | 70.66% | $717.00 Million | $1.01 Billion | +27.99pp |
| 2021-12-31 | 42.67% | $358.97 Million | $841.32 Million | -28.72pp |
| 2020-12-31 | 71.39% | $381.07 Million | $533.80 Million | +6.29pp |
| 2019-12-31 | 65.10% | $188.68 Million | $289.81 Million | -8.99pp |
| 2018-12-31 | 74.10% | $156.47 Million | $211.18 Million | +25.36pp |
| 2017-12-31 | 48.74% | $143.69 Million | $294.81 Million | -3.79pp |
| 2016-12-31 | 52.53% | $89.38 Million | $170.14 Million | +12.29pp |
| 2015-12-31 | 40.24% | $46.37 Million | $115.24 Million | -7.15pp |
| 2014-12-31 | 47.39% | $63.01 Million | $132.97 Million | -21.82pp |
| 2013-12-31 | 69.20% | $57.57 Million | $83.19 Million | -6.99pp |
| 2012-12-31 | 76.20% | $59.09 Million | $77.55 Million | +18.99pp |
| 2011-12-31 | 57.21% | $30.19 Million | $52.77 Million | -12.19pp |
| 2010-12-31 | 69.40% | $54.12 Million | $77.99 Million | -3.33pp |
| 2009-12-31 | 72.73% | $89.17 Million | $122.60 Million | +55.52pp |
| 2008-12-31 | 17.21% | $15.05 Million | $87.45 Million | +15.16pp |
| 2007-12-31 | 2.04% | $3.17 Million | $155.37 Million | -39.34pp |
| 2006-12-31 | 41.39% | $70.16 Million | $169.52 Million | -27.17pp |
| 2005-12-31 | 68.55% | $62.70 Million | $91.46 Million | -3.77pp |
| 2004-12-31 | 72.32% | $92.64 Million | $128.10 Million | +33.83pp |
| 2003-12-31 | 38.49% | $24.20 Million | $62.87 Million | +19.93pp |
| 2002-12-31 | 18.56% | $10.43 Million | $56.17 Million | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more